Intensity Modulated Radiation Fields Induce Protective Effects and Reduce Importance of Dose-Rate Effects.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
01 07 2019
Historique:
received: 13 02 2019
accepted: 19 06 2019
entrez: 3 7 2019
pubmed: 3 7 2019
medline: 21 10 2020
Statut: epublish

Résumé

In advanced radiotherapy, intensity modulated radiation fields and complex dose-delivery are utilized to prescribe higher doses to tumours. Here, we investigated the impact of modulated radiation fields on radio-sensitivity and cell recovery during dose delivery. We generated experimental survival data after single-dose, split-dose and fractionated irradiation in normal human skin fibroblast cells (AGO1522) and human prostate cancer cells (DU145). The dose was delivered to either 50% of the area of a T25 flask containing the cells (half-field) or 100% of the flask (uniform-field). We also modelled the impact of dose-rate effects and intercellular signalling on cell-killing. Applying the model to the survival data, it is found that (i) in-field cell survival under half-field exposure is higher than uniform-field exposure for the same delivered dose; (ii) the importance of sub-lethal damage repair (SLDR) in AGO1522 cells is reduced under half-field exposure; (iii) the yield of initial DNA lesions measured with half-field exposure is smaller than that with uniform-field exposure. These results suggest that increased cell survival under half-field exposure is predominantly attributed not to rescue effects (increased SLDR) but protective effects (reduced induction of initial DNA lesions). In support of these protective effects, the reduced DNA damage leads to modulation of cell-cycle dynamics, i.e., less G

Identifiants

pubmed: 31263149
doi: 10.1038/s41598-019-45960-z
pii: 10.1038/s41598-019-45960-z
pmc: PMC6603191
doi:

Substances chimiques

DNA, Neoplasm 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

9483

Références

Int J Radiat Oncol Biol Phys. 2011 Apr 1;79(5):1516-22
pubmed: 21277116
Radiat Res. 2013 Jul;180(1):44-59
pubmed: 23768075
Radiat Res. 2015 Jun;183(6):656-64
pubmed: 25973952
Radiat Prot Dosimetry. 2011 Feb;143(2-4):325-9
pubmed: 21113064
Mutat Res. 2011 Jan 10;706(1-2):59-64
pubmed: 21073884
Sci Rep. 2018 May 29;8(1):8287
pubmed: 29844494
Cancer Res. 2001 Mar 15;61(6):2744-50
pubmed: 11289157
J Pharm Pharmacol. 2008 Aug;60(8):943-50
pubmed: 18644187
Phys Med Biol. 2011 Apr 21;56(8):2445-57
pubmed: 21427488
Phys Med Biol. 2016 Jan 21;61(2):515-26
pubmed: 26683123
Oncogene. 2007 May 24;26(24):3473-81
pubmed: 17146434
PLoS One. 2013;8(1):e54526
pubmed: 23349919
Phys Med Biol. 2018 Dec 19;64(1):01TR01
pubmed: 30523903
Phys Med Biol. 2012 May 21;57(10):3197-206
pubmed: 22546687
Phys Med Biol. 2008 Jun 21;53(12):3279-92
pubmed: 18523349
Int J Radiat Biol. 1996 Jun;69(6):739-55
pubmed: 8691026
Nat Rev Cancer. 2009 May;9(5):351-60
pubmed: 19377507
Med Phys. 1998 Apr;25(4):375-403
pubmed: 9571605
Med Phys. 2017 Oct;44(10):5522-5532
pubmed: 28786486
J Radiat Res. 2017 May 1;58(3):302-312
pubmed: 27974510
Int J Mol Sci. 2015 Jan 23;16(2):2591-609
pubmed: 25625514
Mutat Res. 2012 Mar 1;731(1-2):117-24
pubmed: 22210495
Radiat Res. 2013 Dec;180(6):584-94
pubmed: 24191898
Radiat Prot Dosimetry. 2015 Sep;166(1-4):148-51
pubmed: 25877530
Semin Radiat Oncol. 2008 Oct;18(4):234-9
pubmed: 18725109
Radiat Res. 1984 Dec;100(3):425-49
pubmed: 6390488
Radiat Res. 1960 Oct;13:556-93
pubmed: 13726391
Sci Rep. 2018 Mar 19;8(1):4849
pubmed: 29555939
Mutat Res. 2007 Mar 1;616(1-2):159-64
pubmed: 17134726
Radiat Res. 1973 May;54(2):316-27
pubmed: 4735769
Cancer Res. 1992 Nov 15;52(22):6394-6
pubmed: 1423287
Mutat Res. 2004 Dec 2;568(1):5-20
pubmed: 15530535
PLoS One. 2012;7(8):e43326
pubmed: 22912853
PLoS One. 2014 Nov 26;9(11):e114056
pubmed: 25426641
Radiat Res. 2018 Jan;189(1):44-52
pubmed: 29136392
J Radiat Res. 2011;52(1):75-81
pubmed: 21160135
Radiat Res. 2012 Jan;177(1):44-51
pubmed: 22029841
Radiat Res. 2007 Nov;168(5):627-30
pubmed: 17973551
Radiat Res. 2001 Mar;155(3):387-96
pubmed: 11182788
Radiat Res. 1999 Nov;152(5):552-7
pubmed: 10521933
Radiat Res. 2017 Dec;188(6):636-644
pubmed: 29019742
Panminerva Med. 2016 Jun;58(2):121-9
pubmed: 26785374
Med Phys. 2011 Jul;38(7):4127-32
pubmed: 21859013
Ann ICRP. 2016 Jun;45(1_suppl):262-279
pubmed: 26960819
Br J Radiol. 2015;88(1056):20150588
pubmed: 26449127

Auteurs

Yusuke Matsuya (Y)

Japan Atomic Energy Agency (JAEA), Nuclear Science and Engineering Center, Research Group for Radiation Transport Analysis, 2-4 Shirakata, Tokai, 319-1195, Ibaraki, Japan. y-matsuya1028@frontier.hokudai.ac.jp.
Graduate School of Health Sciences, Hokkaido University, Kita-12 Nishi-5, Kita-ku, Sapporo, 060-0812, Hokkaido, Japan. y-matsuya1028@frontier.hokudai.ac.jp.

Stephen J McMahon (SJ)

Centre for Cancer Research and Cell Biology, Queen's University Belfast, 97 Lisburn Road, BT7 9AE, Belfast, UK.

Mihaela Ghita (M)

Centre for Cancer Research and Cell Biology, Queen's University Belfast, 97 Lisburn Road, BT7 9AE, Belfast, UK.

Yuji Yoshii (Y)

Biological Research, Education and Instrumentation Center, Sapporo Medical University, Minami-1 Nishi-17, Chuo-ku, Sapporo, 060-8556, Hokkaido, Japan.

Tatsuhiko Sato (T)

Japan Atomic Energy Agency (JAEA), Nuclear Science and Engineering Center, Research Group for Radiation Transport Analysis, 2-4 Shirakata, Tokai, 319-1195, Ibaraki, Japan.

Hiroyuki Date (H)

Faculty of Health Sciences, Hokkaido University, Kita-12 Nishi-5, Kita-ku, Sapporo, 060-0812, Hokkaido, Japan.

Kevin M Prise (KM)

Centre for Cancer Research and Cell Biology, Queen's University Belfast, 97 Lisburn Road, BT7 9AE, Belfast, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH